Filtered By:
Specialty: Endocrinology
Condition: Diabetes
Drug: SGLT2 Inhibitors

This page shows you your search results in order of relevance.

Order by Relevance | Date

Total 36 results found since Jan 2013.

Impact of glucose-lowering therapies on risk of stroke in type 2 diabetes.
Abstract Patients with type 2 diabetes (T2D) have an increased risk of stroke compared with people without diabetes. However, the effects of glucose-lowering drugs on risk of ischaemic stroke in T2D have been less extensively investigated than in coronary heart disease. Some evidence, including the UKPDS, has suggested a reduced risk of stroke with metformin, although the number of studies is limited. Inhibition of the KATP channels increases ischaemic brain lesions in animals. This is in agreement with a recent meta-analysis showing an increased risk of stroke with sulphonylureas vs. various comparators as both m...
Source: Diabetes and Metabolism - May 15, 2017 Category: Endocrinology Authors: Bonnet F, Scheen AJ Tags: Diabetes Metab Source Type: research

Association of glucose-lowering drugs with incident stroke and transient ischaemic attacks in primary care patients with type 2 diabetes: disease analyzer database
ConclusionsTreatment with SGLT2 inhibitors or GLP-1 receptor agonists might reduce non-fatal stroke/TIA in persons with newly diagnosed type 2 diabetes.
Source: Acta Diabetologica - August 6, 2022 Category: Endocrinology Source Type: research

SGLT2 inhibitors: Effect on myocardial infarction and stroke in type 2 diabetes
J Clin Endocrinol Metab. 2023 Feb 28:dgad113. doi: 10.1210/clinem/dgad113. Online ahead of print.ABSTRACTBACKGROUND: SGLT2 inhibitors (sodium-glucose cotransporter-2 inhibitors) have recently been recommended as preferred agents for management of hyperglycemia in type 2 diabetes, primarily based on their ability to reduce a composite of major cardiovascular adverse events (3P MACE), predominantly by reducing cardiovascular death. However reduction of the individual components, myocardial infarction (MI) or stroke (fatal and non-fatal) events have not been well explored.METHODS: In this meta-analysis, we included data avail...
Source: The Journal of Clinical Endocrinology and Metabolism - March 1, 2023 Category: Endocrinology Authors: Pradip Mukhopadhyay Debmalya Sanyal Purushottam Chatterjee Kaushik Pandit Sujoy Ghosh Source Type: research

Do SGLT2 inhibitors and GLP-1 receptor agonists modulate differently the risk of stroke ? Discordance between randomised controlled trials and observational studies
Diabetes Metab. 2023 Sep 5:101474. doi: 10.1016/j.diabet.2023.101474. Online ahead of print.ABSTRACTStroke represents a major burden in patients with type 2 diabetes, yet this cerebrovascular complication has been less carefully investigated than the risk of cardiovascular mortality, heart failure and renal disease. Some data suggested that glucagon peptide-1 receptor agonists (GLP-1RAs) exert a better protection against stroke than sodium-glucose cotransporter 2 inhibitors (SGLT2is). However, this conclusion was derived from indirect comparisons in absence of any head-to-head randomised controlled trial (RCT). The present...
Source: Diabetes and Metabolism - September 7, 2023 Category: Endocrinology Authors: Andr é J Scheen Source Type: research

Meta-analyses of the effects of Dpp-4 inhibitors, SGLT2 inhibitors and GLP1 receptor analogues on cardiovascular death, myocardial infarction, stroke and hospitalization for heart failure
To assess the effects DPP- 4i; SGLT2-i& GLP1-RA on CV death, MI, stroke and hHF . This is probably the first meta-analysis to assess the effects of these drugs on MI and stroke in totality, including non-fatal& fatal MI and stroke.
Source: Diabetes Research and Clinical Practice - February 19, 2019 Category: Endocrinology Authors: Binayak Sinha, Samit Ghosal Source Type: research

Antidiabetic agents and risk of atrial fibrillation/flutter: a comparative critical analysis with a focus on differences between SGLT2 inhibitors and GLP-1 receptor agonists
Diabetes Metab. 2022 Sep 25:101390. doi: 10.1016/j.diabet.2022.101390. Online ahead of print.ABSTRACTAtrial fibrillation/flutter (AF/AFL) is a common cardiac arrhythmia in patients with diabetes and is associated with an increased risk of morbidity, including ischaemic stroke and heart failure, and mortality. Different classes of glucose-lowering agents have shown distinct effects on the risk of stroke and heart failure. Their effects on cardiac arrhythmias such as AF/AFL have not been carefully investigated yet and even less their possible relationship with classical complications such as stroke and heart failure. The pre...
Source: Diabetes and Metabolism - September 28, 2022 Category: Endocrinology Authors: Andr é J Scheen Source Type: research

Revitalization of Pioglitazone: The Optimal Agent to be Combined with an SGLT2 Inhibitor
ABSTRACT The recently completed EMPA‐REG study demonstrated that empagliflozin significantly decreased the MACE endpoint (cardiovascular death, nonfatal MI, stroke) in high risk type 2 diabetic patients, primarily due to a reduction in cardiovascular death, without a significant decrease in either myocardial infarction or stroke. In PROactive, pioglitazone decreased the MACE endpoint by a similar degree to that in EMPA‐REG, due to a marked reduction in both recurrent myocardial infarction and stroke and a modest reduction in cardiovascular death. These observations suggest that pioglitazone might be an ideal agent to c...
Source: Diabetes, Obesity and Metabolism - February 25, 2016 Category: Endocrinology Authors: Ralph A. DeFronzo, Robert Chilton, Luke Norton, Geoffrey Clarke, Robert E.J. Ryder, Muhammad Abdul‐Ghani Tags: ORIGINAL ARTICLE Source Type: research

Cardiovascular mortality and morbidity in patients with type 2 diabetes following initiation of sodium-glucose co-transporter-2 inhibitors versus other glucose-lowering drugs (CVD-REAL Nordic): a multinational observational analysis
Publication date: Available online 3 August 2017 Source:The Lancet Diabetes & Endocrinology Author(s): Kåre I Birkeland, Marit E Jørgensen, Bendix Carstensen, Frederik Persson, Hanne L Gulseth, Marcus Thuresson, Peter Fenici, David Nathanson, Thomas Nyström, Jan W Eriksson, Johan Bodegård, Anna Norhammar Background In patients with type 2 diabetes and a high cardiovascular risk profile, the sodium-glucose co-transporter-2 (SGLT2) inhibitors empagliflozin and canagliflozin have been shown to lower cardiovascular morbidity and mortality. Using real-world data from clinical practice, we aimed to compare cardiovas...
Source: The Lancet Diabetes and Endocrinology - August 4, 2017 Category: Endocrinology Source Type: research

Blood pressure-lowering effects of SGLT2 inhibitors and GLP-1 receptor agonists for preventing of cardiovascular events and death in type 2 diabetes: a systematic review and meta-analysis
ConclusionIn patients with type 2 diabetes, the hypotensive effects of SGLT2i and GLP-1 RAs were significantly associated with a reduction in mortality and cardiorenal events. These findings suggest that the lowering BP effect could be seen as an additive indicator of cardiovascular protection by SGLT2i and GLP-1 RAs drugs.
Source: Acta Diabetologica - July 13, 2023 Category: Endocrinology Source Type: research

Effects of sodium-glucose cotransporter-2 inhibitors on cardiovascular events, death, and major safety outcomes in adults with type 2 diabetes: a systematic review and meta-analysis
Publication date: Available online 18 March 2016 Source:The Lancet Diabetes & Endocrinology Author(s): Jason H Y Wu, Celine Foote, Juuso Blomster, Tadashi Toyama, Vlado Perkovic, Johan Sundström, Bruce Neal Background In patients with type 2 diabetes, sodium-glucose cotransporter-2 (SGLT2) inhibitors are known to reduce glucose concentrations, blood pressure, and weight, but to increase LDL cholesterol and the incidence of urogenital infections. Protection against cardiovascular events has also been reported, as have possible increased risks of adverse outcomes such as ketoacidosis and bone fracture. We a...
Source: The Lancet Diabetes and Endocrinology - March 19, 2016 Category: Endocrinology Source Type: research

SGLT2 Inhibitors and Cardiovascular Risk: Lessons Learned From the EMPA-REG OUTCOME Study
Although cardiovascular (CV) mortality is the principal cause of death in individuals with type 2 diabetes (T2DM), reduction of plasma glucose concentration has little effect on CV disease (CVD) risk. Thus, novel strategies to reduce CVD risk in T2DM patients are needed. The recently published BI 10773 (Empagliflozin) Cardiovascular Outcome Event Trial in Type 2 Diabetes Mellitus Patients (EMPA-REG OUTCOME) study demonstrated that in T2DM patients with high CVD risk empagliflozin reduced the primary major adverse cardiac event end point (CV death, nonfatal myocardial infarction, nonfatal stroke) by 14%. This beneficial eff...
Source: Diabetes Care - April 20, 2016 Category: Endocrinology Authors: Abdul-Ghani, M.; Del Prato, S.; Chilton, R.; DeFronzo, R. A. Tags: Cardiovascular Disease and Diabetes Source Type: research

Cardiovascular Safety of Sodium Glucose Cotransporter 2 Inhibitors as Add-on to Metformin Monotherapy in Patients with Type 2 Diabetes Mellitus.
Conclusion: SGLT2 inhibitors can be a good second-line drug to reduce the incidence of cardiovascular diseases compared with DPP-4 inhibitors or sulfonylureas in people with type 2 diabetes mellitus. PMID: 33120439 [PubMed - as supplied by publisher]
Source: Diabetes and Metabolism Journal - October 31, 2020 Category: Endocrinology Tags: Diabetes Metab J Source Type: research